Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001171843-22-004859
Filing Date
2022-07-14
Accepted
2022-07-14 16:35:49
Documents
7
Effectiveness Date
2022-07-14

Document Format Files

Seq Description Document Type Size
1 S-8 s8_071422.htm S-8 53775
2 EXHIBIT 5.1 exh_51.htm EX-5.1 8074
3 EXHIBIT 23.1 exh_231.htm EX-23.1 2123
4 EXHIBIT 107 exh_107.htm EX-FILING FEES 12829
5 GRAPHIC logo_51.jpg GRAPHIC 7685
6 GRAPHIC foot_52.jpg GRAPHIC 6776
7 GRAPHIC logo2_53.jpg GRAPHIC 3521
  Complete submission text file 0001171843-22-004859.txt   103013
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-266132 | Film No.: 221083373
SIC: 2836 Biological Products, (No Diagnostic Substances)